Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors

Francesca Arezzo; Gaia Giannone; Daniele Castaldo; Giulia Scotto; Valentina Tuninetti; Margherita Turinetto; Michele Bartoletti; Serafina Mammoliti; Grazia Artioli; Giorgia Mangili; Vanda Salutari; Domenica Lorusso; Gennaro Cormio; Vera Loizzi; Claudio Zamagni; Antonella Savarese; Massimo Di Maio; Graziana Ronzino; Carmela Pisano; Sandro Pignata; Giorgio Valabrega

doi:10.3389/fonc.2023.1357793

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors

Front Oncol. 2024 Jan 22:13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.

Authors

Francesca Arezzo^{1

2}, Gaia Giannone³, Daniele Castaldo⁴, Giulia Scotto⁵, Valentina Tuninetti⁶, Margherita Turinetto⁵, Michele Bartoletti⁷, Serafina Mammoliti⁸, Grazia Artioli⁹, Giorgia Mangili¹⁰, Vanda Salutari¹¹, Domenica Lorusso¹², Gennaro Cormio^{1

13}, Vera Loizzi^{1

13}, Claudio Zamagni¹⁴, Antonella Savarese¹⁵, Massimo Di Maio⁶, Graziana Ronzino¹⁶, Carmela Pisano¹⁷, Sandro Pignata¹⁷, Giorgio Valabrega⁶

Affiliations

¹ Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
² Department of Precision and Regenerative Medicine - Ionian Area, University of Bari "Aldo Moro", Bari, Italy.
³ Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
⁴ Segreteria Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group, Naples, Italy.
⁵ Department of Oncology, University of Turin, Turin, Italy.
⁶ Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy.
⁷ Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
⁸ Ospedale Policlinico San Martino - Department of Medical Oncology, IRCCS, Genoa, Italy.
⁹ Oncologia Medica, Unità locale socio sanitaria n2 (ULSS2) Marca Trevigiana, Treviso, Italy.
¹⁰ Obstet-Gynecol Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy.
¹¹ Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
¹² Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
¹³ Interdisciplinar Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
¹⁴ Azienda Ospedaliero-universitaria di Bologna, IRCCS, Bologna, Italy.
¹⁵ Department of Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
¹⁶ Department of Oncology, Ospedale "Vito Fazzi", Lecce, Italy.
¹⁷ Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Naples, Italy.

Abstract

[This corrects the article DOI: 10.3389/fonc.2023.1247291.].

Keywords: dostarlimab; endometrial cancer; immune checkpoint inhibitors; molecular classification; pembrolizumab plus lenvatinib.

Copyright © 2024 Arezzo, Giannone, Castaldo, Scotto, Tuninetti, Turinetto, Bartoletti, Mammoliti, Artioli, Mangili, Salutari, Lorusso, Cormio, Loizzi, Zamagni, Savarese, Di Maio, Ronzino, Pisano, Pignata and Valabrega.

Publication types

Published Erratum